top of page

Cardiovascular

Health

CardioMetabolic 

Health

Lung Health

Bone Health

All-in-one AI-CVD

497e6f54-782b-4e077a-3a7144e4f3e4.png

AutoFracture

(coming soon)

upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
0bdba309-a76a-4215-b207-90a7932bb681.png
iScreen Shoter - 20260520111737117 1.png
Frame 1000004271.png
iScreen Shoter - 20260520105243724 1.png
iScreen Shoter - 20260520105243724 1.png
iScreen Shoter - 20260520100645073 1.png

1 Non-Contrast Scan              10+ Actionable Reports

Should We Screen Asymptomatic Patients with Coronary CT?

  • 3 days ago
  • 1 min read

Coronary CT has become one of the most powerful imaging technologies for cardiovascular risk assessment. However, an important clinical question remains: Should Coronary CT Angiography (CCTA) be used routinely to screen asymptomatic individuals, or does Coronary Artery Calcium (CAC) scanning already provide sufficient information for preventive care?




This presentation reviews the current evidence comparing CAC scoring and CCTA in primary prevention, examining their predictive performance, clinical value, cost-effectiveness, and impact on patient management. While CCTA provides detailed visualization of coronary plaque morphology, non-calcified plaque, stenosis, and other high-risk features, the available evidence suggests that its incremental benefit over CAC alone remains relatively modest for broad population screening, particularly among individuals with a CAC score of zero.

Drawing on data from major studies—including SCAPIS, CONFIRM, SCOT-HEART, and other contemporary investigations—the presentation argues that CAC remains the most practical, scalable, and cost-effective first-line screening tool for asymptomatic adults. Rather than replacing CAC, CCTA may provide its greatest value in carefully selected higher-risk individuals, especially those with elevated CAC scores where plaque characterization can meaningfully influence treatment decisions and preventive strategies.

The presentation concludes by proposing a CAC-first screening strategy, followed by selective CCTA only when additional plaque characterization is likely to change clinical management. This approach aims to maximize diagnostic value while minimizing unnecessary cost, contrast exposure, radiation, and downstream testing, ultimately supporting a more evidence-based and efficient model of cardiovascular prevention.

Download the complete presentation below to explore the latest evidence comparing CAC and CCTA, review the major clinical trials, and understand the evolving role of coronary CT in preventive cardiology.



Comments


Ready to Unlock the Value in Your CT Scans?

Join leading healthcare providers using AI-CVD to save lives and increase revenue, and lead the future of preventive cardiology.

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Youtube

2450 Holcombe Blvd
TMC Innovations
Houston, TX 77021

aicvd patent_edited_edited.jpg
ISO LOGO_edited.png

©2026 HeartLung Corporation. All Rights Reserved. US Patent Nos US9119590*, US10695022, US11610686, US18167691, US20240115224, and Patents Pending. AI-CVD, AI-CAC, AutoBMD, AutoCAC, AutoChamber and other trademarks shown on this website are protected under intellectual property rights of HeartLung Corporation in the United States.

bottom of page